Title : Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.

Pub. Date : 2011 Oct 13

PMID : 23483082






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We hypothesize that combined EGFR and cyclooxygenase-2 (COX-2) inhibition, using small molecule inhibitors erlotinib and celecoxib, respectively would further increase the antitumor activity of radiotherapy. Celecoxib epidermal growth factor receptor Homo sapiens
2 Concurrent treatment with celecoxib and erlotinib +- IR inhibited multiple prosurvival proteins including p-ERK1/2, p-EGFR, p-AKT, p-STAT3, COX-2 and PGE-2. Celecoxib epidermal growth factor receptor Homo sapiens
3 The combination of celecoxib, erlotinib and IR is a promising strategy to overcoming resistance to combined EGFR inhibition and IR alone. Celecoxib epidermal growth factor receptor Homo sapiens